Description

(Triple Agonist: GLP-1R / GIPR / GCGR)

GLP-1R is a synthetic triple-agonist peptide that simultaneously targets the receptors for glucagon-like peptide-1 (GLP-1R), glucose-dependent insulinotropic polypeptide (GIPR), and glucagon (GCGR). This multi-receptor approach has been investigated for its ability to coordinate multiple hormonal axes that influence energy expenditure, glucose metabolism, and body-weight modulation in research models.

By integrating GLP-1, GIP, and glucagon signaling, Retatrutide represents a next-generation incretin-based compound studied for its broad metabolic and cardiometabolic potential in experimental systems.

---

Mechanism of Action (Based on Preclinical and Clinical Research):

• GLP-1R activation: Stimulates insulin secretion, slows gastric emptying, and reduces appetite through central and peripheral pathways.

• GIPR activation: Enhances glucose-stimulated insulin release and complements GLP-1 action for improved glycemic control.

• GCGR activation: Increases basal energy expenditure and promotes fat oxidation through mild glucagon receptor engagement.

• Triple-pathway synergy: Coordinates metabolic hormone signaling to enhance lipid utilization and energy balance beyond single-agonist mechanisms.

---

Potential Benefits (Based on Preclinical Research):

• Significant body-weight reductions in obesity research models

• Improved glucose regulation and insulin sensitivity

• Enhanced energy expenditure and lipid metabolism

• Favorable effects on cardiovascular and metabolic biomarkers

• Studied for potential in multi-incretin and metabolic-disease research

---

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.